StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Welp

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Apr 03, 2021 3:18pm

108 Views

Post# 32934106

RE:RE:RE:Welp

That's what I like to hear. We have a smart, methodical, parsimonious CEO. This co. is mushrooming!
Last year, a small lab, this year a multi-million dollar corporation! It's the Little Lab that COULD!
COULD LUCK TO ALL INVESTORS! lol

davewho wrote: I agree Aristotle has to start someplace and Care may be the place. No reason I can see that Care won't start using / selling Aristotle immediately. Maybe they have already? James used the term immediately accretive in the CC. You have like the 70% margin on Aristotle. Leaves lots of room to offer discounts to large Health Groups. Another thing this acquistion does is bulk up the company. Although still pretty cheap if someone with money like Exas wants to buy them. But that could trigger the same problem Grail is having with the FTC.

An accretive acquisition increases the acquiring company's earnings per share (EPS). Accretive acquisitions tend to be favorable for the company's market price because the price paid by the acquiring firm is lower than the boost that the new acquisition is expected to provide to the acquiring company's EPS.